000			nab a22 7a 4500
999			_c16819 _d16819
003			PC16819
005			20231019062826.0
008			220425b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91227 _aGarrido Ruiz, María Concepción _eAnatomía Patológica
100			_92949 _aGutiérrez García-Rodrigo, Carlota _eDermatología Médico-Quirúrgica y Venereología
100			_92564 _aRiveiro Falkenbach, Erica _eInstituto de Investigación i+12
100			_91223 _aOrtiz Romero, Pablo Luis _eDermatología Médico-Quirúrgica y Venereología
100			_91219 _aRodríguez Peralto, José Luis _eAnatomía Patológica
245	0	0	_aBRAF Inhibitor-Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma. _h[caso clínico]
260			_bThe American Journal of dermatopathology, _c2015
500			_aFormato Vancouver: Garrido MC, Gutiérrez C, Riveiro Falkenbach E, Ortiz P, Rodriguez Peralto JL. BRAF Inhibitor-Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma. Am J Dermatopathol. 2015 Oct;37(10):795-8.
501			_aPMID: 26381028
504			_aContiene12 referencias
520			_aRecent advances in targeting BRAF mutations, which occur in roughly 50% of the melanomas, have improved response rates and overall survival in patients with advanced disease. With the increasingly extensive use of the drug, new, nonpreventable, cutaneous and noncutaneous toxicities keep arising as infrequent adverse effects. We report a 55-year-old man with a history of metastatic melanoma treated with the dabrafenib who presented, 10 months after the initiation of the treatment, with erythematous, slightly squamous, round plaques on his upper trunk and on his left upper arm. Two skin biopsies from the lesions revealed a granulomatous dermatitis in the superficial reticular dermis. One of them showed admixed abundant melanophages from tumoral melanosis. No melanoma cells were seen in any of the specimens. No interruption of the treatment was necessary. Our observation indicates that such a response may represent a positive immune activation triggered by BRAF inhibitors. The erythematous rash was initially concerning for progression of metastatic disease, which suggests that a close monitoring of the patients with advanced melanomas treated with vemurafenib is advisable to prevent unnecessary discontinuation of the therapy.
710			_9330 _aServicio de Anatomía Patológica
710			_9145 _aServicio de Dermatología Médico-Quirúrgica y Venereología
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16819.pdf _ySolicitar documento
942			_2ddc _cCAS _n0